Level- Data

Antibody

Last updated: 2022 Feb 19

Total hit(s): 46

Select item(s)	Key Findings	Comments (You can add your comments too!)	Original Article (hover to see details)

Neutralizing activity of Bamlanivimab, Etesevimab, REGN10933 (casirivimab), REGN10987 (imdevimab), C102, P2B-2F6, and Fab2-36 monoclonal antibodies against SARS-CoV-2 Omicron variant showed a IC₅₀ of >10 µg ml^-1. Sotrovimab (S309) and DZIF-10c had a neutralizing IC₅₀ of 0.0950 and 0.0346 µg ml^-1, respectively.

Several monoclonal antibodies' neutralising efficacy against the Omicron variant is significantly reduced, and this may limit therapy choices for Omicron-induced COVID-19. ✍

35046572
(Nat Med)

PMID	35046572 Date of Publishing: 2022 Jan 19
Title	mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
Author(s) name	Gruell H, Vanshylla K et al.
Journal	Nat Med
Impact factor	22.66 Citation count: 59
Date of Entry	2022 Feb 19

NLM format
Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C, Kurth F, Sander LE, Klein F. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat Med. 2022 Jan 19:1-4. PMID:35046572

In convalescent patients, more than 80% of the anti-spike IgG antibody response is directed against epitopes outside the receptor binding domain (RBD). In one patient, antibodies were aimed at the amino (N)-terminal domain (NTD) that proved protective against a deadly viral attack.

In a high viral load test, a cocktail of the top non-RBD plasma mAbs CM29CM31 (>85% of the IgG plasma lineages to S-ECD) provided the most effective protection and lung viral titers below the limit of detection (LOD) (10^4 PFU). ✍

33947773
(Science)

PMID	33947773 Date of Publishing: 2021 May 4
Title	Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes
Author(s) name	Voss WN, Hou YJ et al.
Journal	Science
Impact factor	20.57 Citation count: 83
Date of Entry	2021 Oct 31

NLM format

Voss WN, Hou YJ, Johnson NV, Delidakis G, Kim JE, Javanmardi K, Horton AP, Bartzoka F, Paresi CJ, Tanno Y, Chou CW, Abbasi SA, Pickens W, George K, Boutz DR, Towers DM, McDaniel JR, Billick D, Goike J, Rowe L, Batra D, Pohl J, Lee J, Gangappa S, Sambhara S, Gadush M, Wang N, Person MD, Iverson BL, Gollihar JD, Dye JM, Herbert AS, Finkelstein IJ, Baric RS, McLellan JS, Georgiou G, Lavinder JJ, Ippolito GC. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. Science. 2021 Jun 4;372(6546):1108-1112. PMID:33947773

3 Monoclonal antibodies (mAb#1, mAb#2, mAb#3) were raised against the NRP1 b1b2 ectodomain to establish functional relevance of S1 CendR-NRP1 interaction. NRP1 enhances the infectivity of SARS-CoV-2 by S1 interaction and also a CendR independent mechanism. mAb1 and mAb3 can control SARS-CoV-2 infections to a large extent.

Small molecule EG00229 inhibits the direct binding of b1 with S1 CendR peptide ✍

33082294
(Science)

PMID	33082294 Date of Publishing: 2020 Nov 13
Title	Neuropilin-1 is a host factor for SARS-CoV-2 infection
Author(s) name	Daly JL, Simonetti B et al.
Journal	Science
Impact factor	20.57 Citation count: 477
Date of Entry	2021 Aug 2

NLM format
Daly JL, Simonetti B, Klein K, Chen KE, Williamson MK, Antón-Plágaro C, Shoemark DK, Simón-Gracia L, Bauer M, Hollandi R, Greber UF, Horvath P, Sessions RB, Helenius A, Hiscox JA, Teesalu T, Matthews DA, Davidson AD, Collins BM, Cullen PJ, Yamauchi Y. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. 2020 Nov 13;370(6518):861-865. PMID:33082294

Neutralizing antibodies coupled on the photothermal nanoparticle helps in inactivation of virus by preventing the entry of virus into ACE-2 expressing host cell.

Toxicity was not observed. ✍

33269351
(bioRxiv)

PMID	33269351 Date of Publishing: 2020 Nov 30
Title	A Neutralizing Antibody-Conjugated Photothermal Nanoparticle Captures and Inactivates SARS-CoV-2
Author(s) name	Cai X, Prominski A et al.
Journal	bioRxiv
Impact factor	- n/a - Citation count: 9

NLM format
Cai X, Prominski A, Lin Y, Ankenbruck N, Rosenberg J, Chen M, Shi J, Chang EB, Penaloza-MacMaster P, Tian B, Huang J. A Neutralizing Antibody-Conjugated Photothermal Nanoparticle Captures and Inactivates SARS-CoV-2. bioRxiv. 2020 Nov 30:2020.11.30.404624. PMID:33269351

The neutralizing potential efficiency of anti-Spike-S1 IgYs (chicken egg yolk antibodies) that blocks the binding of various variants of SARS-CoV-2 spike protein to ACE-2 receptor was researched.

✍

33191178
(Int Immunopharmacol)

PMID	33191178 Date of Publishing: 2020 Nov 3
Title	Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2
Author(s) name	Wei S, Duan S et al.
Journal	Int Immunopharmacol
Impact factor	3.38 Citation count: 6

NLM format
Wei S, Duan S, Liu X, Wang H, Ding S, Chen Y, Xie J, Tian J, Yu N, Ge P, Zhang X, Chen X, Li Y, Meng Q. Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2. Int Immunopharmacol. 2021 Jan;90:107172. PMID:33191178

REGN-COV2 antibodies are efficacious when used prophylactically or therapeutically. This mAB cocktail could reduce the viral load and also decrease virus-induced pathological sequelae in rhesus macaque and limit weight loss in hamsters.

✍

33037066
(Science)

PMID	33037066 Date of Publishing: 2020 Nov 27
Title	REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.
Author(s) name	Baum A, Ajithdoss D et al.
Journal	Science
Impact factor	20.57 Citation count: 245

NLM format

Baum A, Ajithdoss D, Copin R, Zhou A, Lanza K, Negron N, Ni M, Wei Y, Mohammadi K, Musser B, Atwal GS, Oyejide A, Goez-Gazi Y, Dutton J, Clemmons E, Staples HM, Bartley C, Klaffke B, Alfson K, Gazi M, Gonzalez O, Dick E Jr, Carrion R Jr, Pessaint L, Porto M, Cook A, Brown R, Ali V, Greenhouse J, Taylor T, Andersen H, Lewis MG, Stahl N, Murphy AJ, Yancopoulos GD, Kyratsous CA. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.. Science. 2020 Nov 27;370(6520):1110-1115. PMID:33037066

4A8 monoclonal antibody shows a high affinity to bind to the polybasic insert at the furin-like cleavage site.

1.) in silico screening of SARS-CoV-2 neutralizing mAbs: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709177/table/T1/ and 2.) Supplementary data: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709177/#SD1 ✍

33269352
(bioRxiv)

PMID	33269352 Date of Publishing: 2020 Nov 24
Title	A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
Author(s) name	Cheng MH, Porritt RA et al.
Journal	bioRxiv
Impact factor	- n/a - Citation count: 3

NLM format
Cheng MH, Porritt RA, Rivas MN, Krieger JM, Ozdemir AB, Garcia G Jr, Arumugaswami V, Fries BC, Arditi M, Bahar I. A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro. bioRxiv. 2020 Nov 24:2020.11.24.395079. PMID:33269352

6D3 monoclonal antibody can block the SARS-CoV infection by inhibiting the access of host cell proteases, TMPRSS2 or furin.

Figures: 1.)Binding poses: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709177/figure/F2/ 2.) 4A8 binding characteristics examination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709177/figure/F3/ 3.) 6D3 inhibiting SARS-CoV-2 data: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709177/figure/F5/ 4.) Polyacidic residues in the CDR2 of 6D3 and 4A8 heavy chains: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709177/figure/F6/ ✍

33269352
(bioRxiv)

PMID	33269352 Date of Publishing: 2020 Nov 24
Title	A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
Author(s) name	Cheng MH, Porritt RA et al.
Journal	bioRxiv
Impact factor	- n/a - Citation count: 3

NLM format
Cheng MH, Porritt RA, Rivas MN, Krieger JM, Ozdemir AB, Garcia G Jr, Arumugaswami V, Fries BC, Arditi M, Bahar I. A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro. bioRxiv. 2020 Nov 24:2020.11.24.395079. PMID:33269352

A monoclonal Antibody (2B04) potently inhibited SARS-CoV-2 infection with an IC50 of 3.007 ng/mL.

✍

33035201
(JCI Insight)

PMID	33035201 Date of Publishing: 2020 Nov 19
Title	Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors.
Author(s) name	Zeng C, Evans JP et al.
Journal	JCI Insight
Impact factor	6.014 Citation count: 35

NLM format
Zeng C, Evans JP, Pearson R, Qu P, Zheng YM, Robinson RT, Hall-Stoodley L, Yount J, Pannu S, Mallampalli RK, Saif L, Oltz E, Lozanski G, Liu SL. Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors.. JCI Insight. 2020 Nov 19;5(22):e143213. PMID:33035201

Of the 35 monoclonal anti-bodies 'isolate', mAb 4A8 displayed high neutralizing activity against both the authentic and pseudotyped SARS-CoV2.

✍

32571838
(Science)

PMID	32571838 Date of Publishing: 2020 Aug 7
Title	A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Author(s) name	Chi X, Yan R et al.
Journal	Science
Impact factor	20.57 Citation count: 644

NLM format
Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, Dong Y, Yang Y, Chen Z, Guo Y, Zhang J, Li Y, Song X, Chen Y, Xia L, Fu L, Hou L, Xu J, Yu C, Li J, Zhou Q, Chen W. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020 Aug 7;369(6504):650-655. PMID:32571838

Of the 35 monoclonal anti-bodies isolate, mAb IM-ID2 displayed high neutralizing activity against live SARS-CoV2.

✍

32571838
(Science)

PMID	32571838 Date of Publishing: 2020 Aug 7
Title	A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-3
Author(s) name	Chi X, Yan R et al.
Journal	Science
Impact factor	20.57 Citation count: 644

NLM format
Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, Dong Y, Yang Y, Chen Z, Guo Y, Zhang J, Li Y, Song X, Chen Y, Xia L, Fu L, Hou L, Xu J, Yu C, Li J, Zhou Q, Chen W. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-3. Science. 2020 Aug 7;369(6504):650-655. PMID:32571838

Of the 35 monoclonal anti-bodies 'isolate', mAb 0304-3H3 displayed high neutralizing activity against live SARS-CoV2.

✍

32571838
(Science)

PMID	32571838 Date of Publishing: 2020 Aug 7
Title	A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-4
Author(s) name	Chi X, Yan R et al.
Journal	Science
Impact factor	20.57 Citation count: 644

NLM format
Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, Dong Y, Yang Y, Chen Z, Guo Y, Zhang J, Li Y, Song X, Chen Y, Xia L, Fu L, Hou L, Xu J, Yu C, Li J, Zhou Q, Chen W. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-4. Science. 2020 Aug 7;369(6504):650-655. PMID:32571838

Monoclonal antibody MD65 showed neutralizing activity in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2.

Monoclonal antibody MD65 inhibits the binding of RBD to human ACE2 ✍

32855401
(Nat Commun)

PMID	32855401 Date of Publishing: 2020 Aug 27
Title	A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) name	Noy-Porat T, Makdasi E et al.
Journal	Nat Commun
Impact factor	11.8 Citation count: 87

NLM format
Noy-Porat T, Makdasi E, Alcalay R, Mechaly A, Levy Y, Bercovich-Kinori A, Zauberman A, Tamir H, Yahalom-Ronen Y, Israeli M, Epstein E, Achdout H, Melamed S, Chitlaru T, Weiss S, Peretz E, Rosen O, Paran N, Yitzhaki S, Shapira SC, Israely T, Mazor O, Rosenfeld R. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nat Commun. 2020 Aug 27;11(1):4303. PMID:32855401

Monoclonal antibody MD45 showed neutralizing activity in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2.

✍

32855401
(Nat Commun)

PMID	32855401 Date of Publishing: 2020 Aug 27
Title	A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) name	Noy-Porat T, Makdasi E et al.
Journal	Nat Commun
Impact factor	11.8 Citation count: 87

NLM format
Noy-Porat T, Makdasi E, Alcalay R, Mechaly A, Levy Y, Bercovich-Kinori A, Zauberman A, Tamir H, Yahalom-Ronen Y, Israeli M, Epstein E, Achdout H, Melamed S, Chitlaru T, Weiss S, Peretz E, Rosen O, Paran N, Yitzhaki S, Shapira SC, Israely T, Mazor O, Rosenfeld R. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nat Commun. 2020 Aug 27;11(1):4303. PMID:32855401

Monoclonal antibody MD67 showed neutralizing activity in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2.

✍

32855401
(Nat Commun)

PMID	32855401 Date of Publishing: 2020 Aug 27
Title	A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) name	Noy-Porat T, Makdasi E et al.
Journal	Nat Commun
Impact factor	11.8 Citation count: 87

NLM format
Noy-Porat T, Makdasi E, Alcalay R, Mechaly A, Levy Y, Bercovich-Kinori A, Zauberman A, Tamir H, Yahalom-Ronen Y, Israeli M, Epstein E, Achdout H, Melamed S, Chitlaru T, Weiss S, Peretz E, Rosen O, Paran N, Yitzhaki S, Shapira SC, Israely T, Mazor O, Rosenfeld R. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nat Commun. 2020 Aug 27;11(1):4303. PMID:32855401

Monoclonal antibody MD62 showed neutralizing activity in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2.

Monoclonal antibody MD62 inhibits the binding of RBD to human ACE2 ✍

32855401
(Nat Commun)

PMID	32855401 Date of Publishing: 2020 Aug 27
Title	A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) name	Noy-Porat T, Makdasi E et al.
Journal	Nat Commun
Impact factor	11.8 Citation count: 87

NLM format
Noy-Porat T, Makdasi E, Alcalay R, Mechaly A, Levy Y, Bercovich-Kinori A, Zauberman A, Tamir H, Yahalom-Ronen Y, Israeli M, Epstein E, Achdout H, Melamed S, Chitlaru T, Weiss S, Peretz E, Rosen O, Paran N, Yitzhaki S, Shapira SC, Israely T, Mazor O, Rosenfeld R. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nat Commun. 2020 Aug 27;11(1):4303. PMID:32855401

Monoclonal antibody MD63 did not show neutralizing activity in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2.

✍

32855401
(Nat Commun)

PMID	32855401 Date of Publishing: 2020 Aug 27
Title	A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) name	Noy-Porat T, Makdasi E et al.
Journal	Nat Commun
Impact factor	11.8 Citation count: 87

NLM format
Noy-Porat T, Makdasi E, Alcalay R, Mechaly A, Levy Y, Bercovich-Kinori A, Zauberman A, Tamir H, Yahalom-Ronen Y, Israeli M, Epstein E, Achdout H, Melamed S, Chitlaru T, Weiss S, Peretz E, Rosen O, Paran N, Yitzhaki S, Shapira SC, Israely T, Mazor O, Rosenfeld R. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nat Commun. 2020 Aug 27;11(1):4303. PMID:32855401

Monoclonal antibody MD29 showed neutralizing activity in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2.

Monoclonal antibody MD29 which recognizes the same epitope as antibody CR3022 does not inhibit the binding of RBD to human ACE2 ✍

32855401
(Nat Commun)

PMID	32855401 Date of Publishing: 2020 Aug 27
Title	A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) name	Noy-Porat T, Makdasi E et al.
Journal	Nat Commun
Impact factor	11.8 Citation count: 87

NLM format
Noy-Porat T, Makdasi E, Alcalay R, Mechaly A, Levy Y, Bercovich-Kinori A, Zauberman A, Tamir H, Yahalom-Ronen Y, Israeli M, Epstein E, Achdout H, Melamed S, Chitlaru T, Weiss S, Peretz E, Rosen O, Paran N, Yitzhaki S, Shapira SC, Israely T, Mazor O, Rosenfeld R. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nat Commun. 2020 Aug 27;11(1):4303. PMID:32855401

Monoclonal antibody MD17 showed a poor neutralizing activity (NT50) in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2.

✍

32855401
(Nat Commun)

PMID	32855401 Date of Publishing: 2020 Aug 27
Title	A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) name	Noy-Porat T, Makdasi E et al.
Journal	Nat Commun
Impact factor	11.8 Citation count: 87

NLM format
Noy-Porat T, Makdasi E, Alcalay R, Mechaly A, Levy Y, Bercovich-Kinori A, Zauberman A, Tamir H, Yahalom-Ronen Y, Israeli M, Epstein E, Achdout H, Melamed S, Chitlaru T, Weiss S, Peretz E, Rosen O, Paran N, Yitzhaki S, Shapira SC, Israely T, Mazor O, Rosenfeld R. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nat Commun. 2020 Aug 27;11(1):4303. PMID:32855401

A monoclonal antibody (CC12.1) neutralized SARS-CoV-2 in vitro and provided full protection against SARS-CoV-2 infection in Syrian hamsters at a serum concentration of ~22 μg/ml.

✍

32540903
(Science)

PMID	32540903 Date of Publishing: 2020 Aug 21
Title	Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
Author(s) name	Rogers TF, Zhao F et al.
Journal	Science
Impact factor	20.57 Citation count: 708

NLM format

Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, Limbo O, Smith C, Song G, Woehl J, Yang L, Abbott RK, Callaghan S, Garcia E, Hurtado J, Parren M, Peng L, Ramirez S, Ricketts J, Ricciardi MJ, Rawlings SA, Wu NC, Yuan M, Smith DM, Nemazee D, Teijaro JR, Voss JE, Wilson IA, Andrabi R, Briney B, Landais E, Sok D, Jardine JG, Burton DR. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020 Aug 21;369(6506):956-963. PMID:32540903

A monoclonal antibody (CC12.23) neutralized SARS-CoV-2 in vitro and did not protect against SARS-CoV-2 infection in Syrian hamsters at any concentration.

✍

32540903
(Science)

PMID	32540903 Date of Publishing: 2020 Aug 21
Title	Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
Author(s) name	Rogers TF, Zhao F et al.
Journal	Science
Impact factor	20.57 Citation count: 708

NLM format

The P2C-1A3 antibody was found to be the most potent in neutralization of pseudoviruses bearing SARS-CoV-2 spike protein or live SARS-CoV-2.

✍

32454513
(Nature)

PMID	32454513 Date of Publishing: 2020 Aug
Title	Human neutralizing antibodies elicited by SARS-CoV-2 infection
Author(s) name	Ju B, Zhang Q et al.
Journal	Nature
Impact factor	24.36 Citation count: 847

NLM format
Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, Tang X, Yu J, Lan J, Yuan J, Wang H, Zhao J, Zhang S, Wang Y, Shi X, Liu L, Zhao J, Wang X, Zhang Z, Zhang L. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020 Aug;584(7819):115-119. PMID:32454513

The P2B-2F6 antibody was found to be the most potent in neutralization of pseudoviruses bearing SARS-CoV-2 spike protein or live SARS-CoV-2.

✍

32454513
(Nature)

PMID	32454513 Date of Publishing: 2020 Aug
Title	Human neutralizing antibodies elicited by SARS-CoV-2 infection
Author(s) name	Ju B, Zhang Q et al.
Journal	Nature
Impact factor	24.36 Citation count: 847

NLM format
Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, Tang X, Yu J, Lan J, Yuan J, Wang H, Zhao J, Zhang S, Wang Y, Shi X, Liu L, Zhao J, Wang X, Zhang Z, Zhang L. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020 Aug;584(7819):115-119. PMID:32454513

The P2C-1F11 antibody was found to be the most potent in the neutralization of pseudoviruses bearing SARS-CoV-2 spike protein or live SARS-CoV-2.

✍

32454513
(Nature)

PMID	32454513 Date of Publishing: 2020 Aug
Title	Human neutralizing antibodies elicited by SARS-CoV-2 infection
Author(s) name	Ju B, Zhang Q et al.
Journal	Nature
Impact factor	24.36 Citation count: 847

NLM format
Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, Tang X, Yu J, Lan J, Yuan J, Wang H, Zhao J, Zhang S, Wang Y, Shi X, Liu L, Zhao J, Wang X, Zhang Z, Zhang L. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020 Aug;584(7819):115-119. PMID:32454513

A monoclonal antibody (COV2-2381) protected rhesus macaques against SARS-CoV-2 infection.

✍

32668443
(Nature)

PMID	32668443 Date of Publishing: 2020 Aug
Title	Potently neutralizing and protective human antibodies against SARS-CoV-2
Author(s) name	Zost SJ, Gilchuk P et al.
Journal	Nature
Impact factor	24.36 Citation count: 460

NLM format

Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, Schäfer A, Reidy JX, Trivette A, Nargi RS, Sutton RE, Suryadevara N, Martinez DR, Williamson LE, Chen EC, Jones T, Day S, Myers L, Hassan AO, Kafai NM, Winkler ES, Fox JM, Shrihari S, Mueller BK, Meiler J, Chandrashekar A, Mercado NB, Steinhardt JJ, Ren K, Loo YM, Kallewaard NL, McCune BT, Keeler SP, Holtzman MJ, Barouch DH, Gralinski LE, Baric RS, Thackray LB, Diamond MS, Carnahan RH, Crowe JE Jr. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020 Aug;584(7821):443-449. PMID:32668443